DPP4 and COVID-19: The use of DPP4 inhibitors is an attractive approach to be investigated in the treatment of COVID-19 patients who have pre-existing comorbidities, as its inhibition may prevent viral entry and subsequent replication in airways, and prevent the cytokine storm associated with severe COVID-19 complications [38,264].